ClinicalTrials.gg
SuspendedNCT02013284Updated Oct 20, 2026

Is Our Microbiome a Predictor of Cardiac Risk

An observational study in Coronary Artery Disease, sponsored by Mayo Clinic. Suspended at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Mayo Clinic · Observational

How we know

Why this study was suspended
Reorganizing study personnel and funding
Updated Oct 20, 2026Now SuspendedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Coronary Artery Disease by Mayo Clinic — 3 open to participants now, 3 under way, none of them phase 3. Coronary Artery Disease · Mayo Clinic.

Started
2013
with 3 others
Observational
8 of 23
1 open now
Registered
14th of 23
by date

Among the 23 studies in Coronary Artery Disease by Mayo Clinic, this one is one of 4 that started in 2013, is one of 8 observational ones, and was the 14th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

3 of the 23 studies in Coronary Artery Disease by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Coronary Artery Disease by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this study is to determine a relationship between a person's flora/bacteria in their gut (the intestinal microbiome) and their risk of cardiovascular disease. Investigators will look at inflammatory markers in the blood and also look at the genome of the bacteria in the gut.

Read the detailed description

Investigators will look at inflammatory markers in the blood and also look at the genome of the bacteria in the gut. This research is being done because Investigators believe that there is a connection between the way food is digested by a person's gut bacteria and the development of atherosclerosis (hardening of the arteries) and cardiovascular disease. The ultimate goal of this research is to eventually determine if changes to the gut bacteria can prevent cardiovascular disease or disease progression.

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consenting participants who are undergoing coronary angiography.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Anyone undergoing cardiac catheterization for suspected coronary artery disease over age 18.

Exclusion criteria

Exclusion Criteria:

  1. Patients currently on long-term antibiotics who cannot stop them for at least 2 weeks prior to providing a stool sample.
  2. Patients on chronic laxatives who cannot stop for at least 2 weeks prior to stool collection.
  3. Patients on probiotics and cannot stop for 2 weeks prior to giving a stool sample (yogurt is ok).
  4. Patients who are unable to provide a stool sample to Mayo Clinic within 24 hours of collection utilizing Fed Ex overnight mail (i.e. people overseas who are unable to provide a sample before leaving the USA.)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. 50 cc blood obtained during angiogram and used for Endothelial Progenitor Cells analysis using antibodies for inflammatory markers. Plasma collection will be done for antibody analysis. Buffy coats will be frozen and stored for future genetic analysis.

    Time frame: Blood samples will be obtained during the diagnostic angiogram.

Secondary outcomes

  1. Stool samples will be collected to compare the fecal microbiota of patients with mild, moderate and severe coronary artery disease.

    Time frame: Two weeks after the angiogram

07

Study locations

1 site
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Nov 2013, a primary completion of Dec 2027 and a completion of Dec 2027. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Sep 2026 → Dec 2027 and completion Sep 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2013
First posted
Dec 17, 2013
Start
Nov 2013
Primary completionEst.
Dec 2027was Sep 2026
CompletionEst.
Dec 2027was Sep 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Suspended Reorganizing study personnel and funding
changed Oct 20, 2026
Primary completion
Sep 2026→Dec 2027
Oct 20, 2026
Study completion
Sep 2026→Dec 2027
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Enrolling by invitation→Suspended
    Why stopped Reorganizing study personnel and funding
    Primary completion Sep 2026→Dec 2027
    Study completion Sep 2026→Dec 2027
    + 4 other changes: verification date, responsible party, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02013284
Lead sponsor
Mayo Clinic
Responsible party
Valentina Nardi (Valentina Nardi, MD, Mayo Clinic) — Principal investigator
First posted
Dec 17, 2013
Start date
Nov 2013
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Valentina Nardi, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion